查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1620385

先进药物输送的全球市场规模：按产品、按应用、按地区、范围和预测

Global Advanced Drug Delivery Market Size By Product (Polymeric Drug Delivery, Implants & IUD's), By Application (Hospitals, Diagnostic Centers), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

先进药物传输市场规模及预测

2024年先进药物输送市场规模为774.9亿美元，预计2024年至2031年复合年增长率为18.60%，2031年达到3033.2亿美元。先进的药物递送调节药物释放速率。疾病的类型、药物和期望的结果都会影响所使用的创新。先进药物传递系统的目标是尽快将治疗剂量的药物输送到体内的特定部位，并达到并维持药物的目标浓度。全球先进药物输送市场报告提供了对市场的整体评估。它对关键细分市场、趋势、市场推动因素、市场限制、竞争格局以及在市场中发挥关键作用的因素进行了全面分析。

定义全球先进药物传输市场

先进的药物输送系统是以更受控的方式将药物分子输送到所需目标的最佳化方法。正在开发这些方法来提高现有药物的治疗效果。先进药物递送系统的进步取决于以预定速率和缓慢、有针对性的方式递送药物以实现原位药物释放和吸收。

能够更有选择性地将药物递送到特定部位，更容易、更精确和更少的一般剂量，全身药物水平的变异性更小，根据部位和作用机制吸收更一致，有毒化合物更少这些都是先进药物递送系统的主要优点超过传统系统。

先进的药物递送系统分为标靶药物传递、聚合物药物传递、缓释药物递送、植入物/子宫内避孕器和前药。标靶药物递送是将药物部分直接递送至所需的身体部位的过程，以消除传统药物递送的特定毒性作用并减少治疗效果所需的药物量。前药是没有药理活性的分子，它们在体内经由酵素、化学或两者的混合物转化为活性母体药物。

前药已经从偶然发现并用作治疗药物，转变为明确设计的药物。先进的药物传递系统包括口服、肠胃外、肺部、皮下、透皮和奈米结构，例如奈米结构、奈米球、奈米胶囊、奈米颗粒、脂质体、脂质体、树枝状聚合物、合成聚合物和基于脂质的载体系统（例如囊泡载体）。

先进药物输送的全球市场概况

推动成长的主要因素之一是慢性病在人群中的快速传播。慢性病被广泛认为是持续一年以上并需要持续医疗护理、限制日常活动或两者兼而有之的问题。此外，全球医疗保健支出的大幅增加正在加强先进药物输送市场。

医疗费用增加的主要原因是人口成长，特别是人口老化、慢性病增加、医疗服务使用范围扩大。增加研发活动以产生新的药物分子。各种先进药物传递途径的发展推动了科学技术的进步，以增强药物化合物的药效学、药物毒性、免疫原性、生物相容性、药物动力学特性和功效。

此外，增加用于开发先进药物输送系统、新产品和合作伙伴关係的政府资金和贷款预计将在预测期内促进市场成长。药物召回和药物失效的大幅增加预计将限制先进药物输送市场的成长。方法开发中的某些技术困难、更严格的法规、先进产品的高价格、低收入国家的不可用等是限制全球先进药物输送市场成长的因素。

医疗保健费用的增加是由于消费者健康意识的提高、政府和企业的努力以及私人公司为满足欠发达国家和发展中国家的消费者需求而进行的政府投资。因此，所有这些因素都为投资研究和创新流程以及开发先进的药物输送解决方案提供了机会，以提高现有药物以及未来将开发的新分子实体的疗效和可靠治疗，从而加速市场增长。

目录

第1章全球先进给药市场：简介

  • 市场概况
  • 调查范围
  • 先决条件

第 2 章执行摘要

第3章 验证市场研究研究方法

  • 数据挖掘
  • 确认
  • 初步面试
  • 数据源列表

第4章 全球先进给药市场前景

  • 概述
  • 市场动态
    • 促进因素
    • 阻碍因素
    • 机会
  • 波特的五力模型
  • 价值链分析

第5章先进药物输送的全球市场：副产品

  • 概述
  • 植入物和子宫内避孕器
  • 缓释药物输送
  • 靶向药物输送
  • 前药
  • 聚合物药物递送

第6章先进药物传输的全球市场：依应用分类

  • 概述
  • 诊断中心
  • 门诊手术中心/诊所
  • 家庭医疗
  • 医院
  • 其他

第7章先进药物输送的全球市场：按地区

  • 概述
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 亚太其他地区
  • 世界其他地区
    • 拉丁美洲
    • 中东/非洲

第8章全球先进给药市场：竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第9章 公司简介

  • GlaxoSmithKline
  • Merck & Co
  • Antares Pharma
  • Allergan
  • F. Hoffmann-La Roche
  • Novartis
  • Sanofi
  • 3M
  • Johnson & Johnson
  • Pfizer

第10章 主要进展

  • 产品发布/开发
  • 併购
  • 业务拓展
  • 伙伴关係和联盟

第11章附录

  • 相关研究
简介目录
Product Code: 14113

Advanced Drug Delivery Market Size And Forecast

Advanced Drug Delivery Market size was valued at USD 77.49 Billion in 2024 and is projected to reach USD 303.32 Billion by 2031, growing at a CAGR of 18.60% from 2024 to 2031. Advanced drug delivery regulates the rate at which drugs are released. The type of disease, drug, and preferred outcome all have an impact on the innovation used. An advanced drug delivery system's goal is to deliver a therapeutic amount of medication to a specific site in the body as quickly as possible to achieve and then preserve the target concentration of the drug. The Global Advanced Drug Delivery Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Advanced Drug Delivery Market Definition

Advanced drug delivery systems are optimized methods for delivering the drug molecule to the desired target in a more controlled way. These methods are being developed to enhance the improved therapeutic ratio of existing drugs. The advancement of advanced drug delivery systems is predicated on the delivery of drugs at a predetermined rate, and also slow and targeted delivery for onsite drug release and absorption.

The ability to deliver a drug more selectively to a particular site, easier, more precise, less common dosing, reduced variability in systemic drug levels, absorption that is more constant with the site and mode of action, and reductions in toxic compounds are all major benefits of advanced drug delivery systems over traditional systems.

The Advanced Drug Delivery System is classified as Targeted Drug Delivery, Polymeric Drug Delivery, Sustained Release, Implants & IUDs, and Prodrugs. Targeted drug delivery is a process of providing a drug moiety directly into its intended body area to resolve the specific toxic effect of conventional drug delivery and thus decrease the amount of drug needed for therapeutic efficacy. Prodrugs are molecules with no pharmacological activity that are transformed to the active parent drug in vivo through enzymatic, chemical, or a mixture of the two.

Prodrugs have advanced from being discovered by possibility and used as a salvage effort to just being designed explicitly. The advanced drug delivery system contains oral, parenteral, pulmonary, subcutaneous, transdermal, and carrier-based systems such as nanostructures, Nanospheres, Nanocapsules, nanoparticles, and Nano-sized vesicular carriers including such liposomes, noisome, dendrimers, and synthetic polymer or lipid-based carriers, and other drug delivery systems.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Advanced Drug Delivery Market Overview

One of the major factors driving the growth is the rapid spread of chronic diseases in the overall population. The chronic disease known broadly as a problem that lasts a year or longer and necessarily require ongoing medical care, confine daily activities, or both. Moreover, the substantial increase in global health expenditures has enhanced the Advanced Drug Delivery Market.

The main causes of the increase in medical expenditure are a rise in population, especially geriatrics, an increase in chronic conditions, and enhanced medical service utilization. Growing R&D activities to bring new drug molecules. By developing different advanced drug delivery routes, science and technological advances have been made to develop advanced drug delivery systems to increase the pharmacodynamics, drug toxicity, immunogenicity, biocompatibility, pharmacokinetic properties, and efficacy of drug compounds.

Furthermore, increased government funding and financing, new products, and collaborative partnerships for the development of advanced drug delivery systems are projected to boost market growth over the forecast period. The substantial rise in the number of drugs recalls and drug failures are expected to restrict the growth of the Advanced Drug Delivery Market. Certain technical difficulties in method development, stricter regulations, high pricing for advanced products, and non-availability in low-income countries are among the factors that limit Global Advanced Drug Delivery Market growth.

The increase in healthcare costs has been attributed to the increased consumer awareness of health, enhanced government and corporate initiatives, and government investment by public-private sector companies to fulfill consumer demands in underdeveloped and developing countries. As an outcome, all of these factors provide opportunities for investments in the Research and innovation process and the development of advanced drug delivery solutions for improved drug efficacy and secure therapy for existing drugs as well as upcoming novel molecular entities, which accelerates the market growth.

Global Advanced Drug Delivery Market Segmentation Analysis

The Global Advanced Drug Delivery Market is segmented on the basis of Product, Application, And Geography.

Advanced Drug Delivery Market, By Product

  • Polymeric Drug Delivery
  • Implants & IUD's
  • Sustained Release
  • Targeted Drug Delivery
  • Prodrugs

Based on Product, The market is segmented into Polymeric Drug Delivery, Implants & IUD's, Sustained Release, Targeted Drug Delivery, and Prodrugs. Targeted Drug Delivery has the highest growing segment of the Global Drug Delivery System Market because of increased drug accessibility, reduced toxicity, effective targeted therapy, and lowered active drug degradation over the forecasted period.

Advanced Drug Delivery Market, By Application

  • Hospitals
  • Diagnostic Centers
  • Ambulatory Surgical Centers/Clinics
  • Home Care Settings
  • Others

Based on the Application, The market is segmented into Hospitals, Diagnostic Centers, Ambulatory Surgical Centers/Clinics, Home Care Settings, and Others. Hospitals have the fastest-growing segment of the Global Drug Delivery System Market. because of a rise in the number of in-patients and out-patient visits, However, this leading to an increase in chronic illnesses including such neurology, cardiology, and orthopedics, as well as a growth of the market for drug delivery treatment, the highly specialized clinics segment accounting for almost half of the global Advanced Drug Delivery Market.

Advanced Drug Delivery Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of Geography, The Global Advanced Drug Delivery Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is projected to be the largest growing market throughout the forecasted period. This is attributed to the increase in the integration of advanced as a result of improved drug delivery solutions, and increasing healthcare expenses in the region over the projected period.

Key Players

  • The "Global Advanced Drug Delivery Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
  • GlaxoSmithKline, Merck & Co, Antares Pharma, Allergan, F. Hoffmann-La Roche, Novartis, Sanofi, 3M, Johnson & Johnson, Pfizer, Abbott Laboratories, Bayer.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • In February 2019, Sandoz, a Novartis division and world leader in biosimilars, received European Commission authorization in Spain for its adalimumab biosimilar, HYRIMOZ, for subcutaneous injection in a syringe or a prefilled pen.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ADVANCED DRUG DELIVERY MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL ADVANCED DRUG DELIVERY MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL ADVANCED DRUG DELIVERY MARKET, BY PRODUCT

  • 5.1 Overview
  • 5.2 Implants & IUD's
  • 5.3 Sustained Release
  • 5.4 Targeted Drug Delivery
  • 5.5 Prodrugs
  • 5.6 Polymeric Drug Delivery

6 GLOBAL ADVANCED DRUG DELIVERY MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Diagnostic Centres
  • 6.3 Ambulatory Surgical Centers/Clinics
  • 6.4 Home Care Settings
  • 6.5 Hospitals
  • 6.6 Others

7 GLOBAL ADVANCED DRUG DELIVERY MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.3 Canada
    • 7.2.4 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East and Africa

8 GLOBAL ADVANCED DRUG DELIVERY MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 GlaxoSmithKline
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Merck & Co
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Antares Pharma
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Allergan
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 F. Hoffmann-La Roche
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Novartis
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Sanofi
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 3M
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Johnson & Johnson
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 Pfizer
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 KEY DEVELOPMENTS

  • 10.1 Product Launches/Developments
  • 10.2 Mergers and Acquisitions
  • 10.3 Business Expansions
  • 10.4 Partnerships and Collaborations

11 Appendix

  • 11.1 Related Research